Condition: Obesity (Disorder) · Breast Cancer · Sponsor: Weill Medical College of Cornell University
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
This description comes directly from the study's public registry record.
Lynelle Weis · 646-962-2423 · ljw4002@med.cornell.edu
Henry Cheng · 646-962-6026 · hec4011@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07257484